Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 1/20 | 0.58 |
| ▸ | MMP2 | P08253 | 17/20 | 0.50 |
| ▸ | MMP3 | P08254 | 12/20 | 0.50 |
| ▸ | MMP1 | P03956 | 10/20 | 0.50 |
| ▸ | MMP7 | P09237 | 6/20 | 0.47 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667611 | 1.00 | CSNK1E (0.58) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL4926240 | 1.00 | CSNK1E (0.58) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL717704 | 1.00 | CSNK1E (0.58) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL3400024 | 1.00 | CSNK1E (0.58) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL2782163 | 1.00 | CSNK1E (0.58) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL11624296 | 0.93 | CSNK1E (0.49) | CSNK1EMMP2MMP3MMP1FOLH1 | |
| SCHEMBL5017227 | 0.87 | MMP2 (0.57) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL28211408 | 0.87 | MMP2 (0.57) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL10801653 | 0.85 | CSNK1E (0.56) | CSNK1EMMP2MMP3MMP1MMP7 | |
| SCHEMBL10955140 | 0.85 | FOLH1 (0.66) | CSNK1EMMP2MMP3MMP1MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1853605-B1 | INTEGRIN TARGETED SYNTHETIC LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | BRACCO IMAGING SPA (IT) | 2014-09-10 | — | — | EP | claimed |
| EP-0954518-A1 | NEW POLYDYNAMIC CHEMICAL COMPOSITION OF MULTIPLE APPLICATIONS AND METHOD OF PREPARATION THEREOF | Venetsianos, Timoleon (GR) | 1999-11-10 | — | — | EP | claimed |
| WO-1998035933-A1 | NEW POLYDYNAMIC CHEMICAL COMPOSITION OF MULTIPLE APPLICATIONS AND METHOD OF PREPARATION THEREOF | VENETSIANOS TIMOLEON (GR) | 1998-08-20 | — | — | WO | claimed |
| US-9334161-B2 | Processing liquid for suppressing pattern collapse of fine metal structure and method for producing fine metal structure using same | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2016-05-10 | — | — | US | disclosed |
| US-9320834-B2 | Hardenable antimicrobial composition | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150165097-A1 | HARDENABLE ANTIMICROBIAL COMPOSITION | SOLVENTUM INTELLECTUAL PROPERTIES COMPANY | 2015-06-18 | — | — | US | disclosed |
| US-20120181249-A1 | PROCESSING LIQUID FOR SUPPRESSING PATTERN COLLAPSE OF FINE METAL STRUCTURE AND METHOD FOR PRODUCING FINE METAL STRUCTURE USING SAME | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-20080248511-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | PROMEGA CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-7303876-B2 | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | APPLERA CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-7067500-B2 | Betaines as adjuvants to susceptibility testing and antimicrobial therapy | INTEGRATED RESEARCH TECHNOLOGY, LLC (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050009045-A1 | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases | APPLERA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-6762027-B2 | EXTRACTING PREFERENTIAL NUCLEOTIDE SEQUENCE FROM TISSUE; OBTAIN TISSUE SAMPLE, EXPOSE TO DISRUPTION MIXTURE, BIND NUCLEIC ACID TO SOLID PHASE, RECOVER NUCLEOTIDE SEQUENCES | APPLERA CORPORATION | 2004-07-13 | — | — | US | disclosed |
| EP-0762828-A4 | METHOD AND REAGENT SYSTEM FOR THE IMPROVED DETERMINATION OF WHITE BLOOD CELL SUBPOPULATIONS | CARVER EDWARD LAWRENCE JR (US) | 2002-03-20 | — | — | EP | disclosed |
| US-5895765-A | USING A STRIP OF A NEGATIVELY CHARGED MATRIX MATERIAL HAVING A ZONE CONTAINING MOBILE, LABELED BINDING PARTNER FOR THE ANALYTE AND A SEPARATE ZONE FOR CAPTURING THE LABELED BINDING PARTNER; POLYALKOXYLATED AMINE SURFACTANT | BAYER CORPORATION (US) | 1999-04-20 | — | — | US | disclosed |
| EP-0762828-A1 | METHOD AND REAGENT SYSTEM FOR THE IMPROVED DETERMINATION OF WHITE BLOOD CELL SUBPOPULATIONS | Carver, Edward Lawrence, Jr. (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995032622-A1 | METHOD AND REAGENT SYSTEM FOR THE IMPROVED DETERMINATION OF WHITE BLOOD CELL SUBPOPULATIONS | CDC TECHNOLOGIES INC (US) | 1995-12-07 | — | — | WO | disclosed |
| US-5316951-A | Method for the improved determination of white blood cell subpopulations | DREW SCIENTIFIC HOLDINGS, INC. | 1994-05-31 | — | — | US | disclosed |
| US-5316725-A | Separation by particle size | Carver, Jr., Edward Lawrence (US) | 1994-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080248511-A1 | METHODS TO QUENCH LIGHT FROM OPTICAL REACTIONS | GLO1, ESD, GLB1 | CSNK1E 1680/4885MMP2 1338/4885MMP3 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.